Cytochrome P450 (cyp)
In early studies, P450s were shown to be monooxygenases involved in the insertion of an oxygen atom from dioxygen (O2) into substrates including 17-hydroxy-progesterone (by bovine P450c21, now known as CYP21A1) and D-camphor (by Pseudomonas putida P450cam, CYP101A1 (Cooper et al. 1963; Katagiri et al. 1968). Subsequent research has revealed that the P450s are found in almost all life forms, including mammals (with 57 CYP genes in humans), amphibians, fish, plants, algae, insects, bacteria, and archaea (Crespi et al. 1991; Heilmann et al. 1988; Fujita et al. 2004; Rodgers et al. 1993; Ramaswamy et al. 2007; Mayer et al. 1978; Belcher et al. 2014; Yano et al. 2000). CYP genes have also been identified in viruses, presumably obtained from infected host organisms (Lamb et al. 2009). The number of CYP genes identified was >35,000 as of April 2016 (Nelson 2016), and numbers continue to grow at a pace with new data emanating from genome sequences. The P450s are now known to have numerous roles across different life forms, including metabolism and interconversion of steroids (Yoshimoto and Auchus 2015), oxidation of fatty acids and eicosanoids (Johnson et al. 2015), drug and xenobiotic metabolism (Guengerich 2006), synthesis of antibiotics (Haslinger et al. 2014), catabolism of unusual carbon sources in microbes (Hedegaard and Gunsalus 1965), and synthesis of alkenes, diterpenoids, and alkaloids (Rude et al. 2011; Matsuba et al. 2015; Farrow et al. 2015).
Classification and Diverse Functions of Cytochromes P450
The advent of genome sequencing resulted in the identification of large numbers of new cytochrome P450 (CYP) genes in organisms from all the domains of life. Notable examples include cow (Bos taurus) with at least 62 CYP genes (Nelson 2015); Mycobacterium tuberculosis H37Rv with 20 CYP genes, compared to Mycobacterium leprae (which has a single functional CYP gene and which has undergone extensive gene deletion and decay, resulting in less than half of the genome containing functional genes) (Cole et al. 1998, 2001); the malaria mosquito Anopheles gambiae with ~104 CYP genes (Holt et al. 2002), tomato (Solanum lycopersicum) with ~457 CYP genes (including pseudogenes) (The Tomato Genome Consortium (TGC) 2012; Nelson 2012); and ~111 CYP genes in Aspergillus nidulans (Nelson 2007). Eukaryotes typically have larger numbers of CYP genes than prokaryotes. However, this is not always true, and the genomes of the bacteria Streptomyces avermitilis and Mycobacterium smegmatis have 33 and 39 CYP genes, respectively (Ikeda et al. 2003, UCSC Microbial Genome Browser), while the eukaryotic protozoan parasite Leishmania donovani has only three P450s and the parasite Trypanosoma brucei (and other Trypanosoma species) may only have two CYP genes based on current data (Nelson 2004; Verma et al. 2011). S. avermitilis produces the antiparasitic compounds the avermectins, and it was proposed that around one third of its CYP genes are involved in synthesis of secondary metabolites (Ikeda et al. 2003). The bacterium Escherichia coli is devoid of CYP genes but has proven to be an excellent expression system for the production of P450 enzymes from both prokaryotes and eukaryotes (Green et al. 2001; Gillam et al. 1993).
The burgeoning numbers of P450 enzymes identified from gene sequences led to the comparative analysis of the enzymes and their gene sequences and to their classification into the P450 superfamily – the first such attempt to classify related proteins according to their levels of amino acid sequence similarity (Nebert et al. 1987, 1991). P450s are classified into the same family if they share ≥40% amino acid sequence identity with other members of that family, or into the same subfamily if they have ≥55% amino acid sequence identity. Typically, the substrate selectivity is similar for members of the same family, with substrate specificity and reactivity even more similar among subfamily members. Using this system, the 57 human P450s are classified into 18 different families (CYPs 1–5,7,8,11,17–21,24,26,27,39,46 and 51) and then into subfamilies (denoted A,B etc), with further numbering indicating the specific identity of the subfamily member. For example, CYP1A1 and 1A2 catalyze typical reactions including benzo[a]pyrene 3-hydroxylation and caffeine N3-demethylation, respectively. CYPs 4B1, 4F12 and 4F22 are lipid hydroxylases, catalyzing lauric acid ω-hydroxylation, arachidonic acid ω- and ω-1 hydroxylation, and vitamin K ω-hydroxylation; while CYP51A1 is a member of the sterol 14-alpha demethylases found across eukaryotes, and which catalyze lanosterol 14a–demethylation en route to cholesterol biosynthesis (Guengerich 2015). Plant P450s are currently classified in the CYP51,71–99 and 701–722 families, including P450s with functions including linalool hydroxylation and epoxidation (CYP71B31) in a monoterpene pathway in Arabidopsis thaliana, multi-step oxidation of ent-kaurenic acid in A. thaliana gibberellin synthesis by CYP88A3 and A4, and CYP71AV1 in the medicinal plant Artemisia annua, that converts amorphadiene to artemisinic acid in the pathway for synthesis of the sesquiterpene lactone and leading antimalarial drug artemisinin (Schuler 2015). Bacterial and archaeal P450s are classified in the CYP51, 101–299 and 1001–1050 families, with prominent members being the Pseudomonas putida D-camphor hydroxylase P450cam (CYP101A1) and the Bacillus megaterium fatty acid hydroxylase P450 BM3 (CYP102A1) (McLean et al. 2015; Nelson 2009).
This classification system continues to be used, although the large numbers of CYP genes being identified present significant challenges in their accurate assignments. However, other features of P450s lead to simpler routes to different forms of classification. A major schism occurs between eukaryotic P450s and those from bacteria and archaea. The eukaryotic P450s are almost exclusively membrane associated, attached to either the matrix side of the mitochondrial inner membranes in animal P450s (mitochondrial P450s are not a feature of plants and fungi) (Feyereisen 2006) or to endoplasmic reticulum (ER) membranes (Poulos and Johnson 2015). The 57 functional human P450s (not including pseudogenes) consist of 50 “microsomal” P450s located primarily in the ER of liver and other tissues and 7 P450s in the mitochondria of adrenal glands, gonads, liver, kidney, and other sites. The adrenal mitochondrial P450s are involved in the transformation of cholesterol into pregnenolone (CYP11A1) and other steroid oxidations (CYPs 11B1 and 11B2), with CYPs located mainly in liver and kidney mitochondria having roles in 24-hydroxylation of vitamin D3 and 27-hydroxylation of cholesterol in formation of bile acids (CYP27A1), 24-hydroxylation of 25-hydroxyvitamin D3 (CYP24A1), and 1α-hydroxylation of 25-hydroxyvitamin D3 (CYP27B1) (Omura 2006). While the physiological function of the final human mitochondrial P450 (CYP27C1) remains uncertain, recent studies on zebra fish and bullfrog CYP27C1 revealed that the enzyme is a dehydrogenase that converts vitamin A1 (a rhodopsin and the precursor of 11-cis retinal) into vitamin A2 (a porphyropsin and precursor of 11-cis 3,4-didehydroretinal). This causes a redshift in photoreceptor sensitivity and improves the organisms’ ability to see and respond to near-infrared light. The authors suggested one potential role for the human CYP27C1 ortholog may be in retinoid biosynthesis in skin (Enright et al. 2015).
In contrast, the bacterial/archaeal P450s are almost invariably soluble, cytoplasmic enzymes that lack a membrane-spanning helix (McLean et al. 2015). The eukaryotic P450s have an extended N-terminal region (~30 to 50 amino acids) that crosses the membrane with an ~20 hydrophobic amino acid helical segment that corresponds approximately to the ~3 Å span of the hydrophobic core of the membrane (Andersen and Koeppe 2007). This membrane “tethering” portion precedes the catalytic core structure of the P450 itself, as shown recently by the first crystal structure of a membrane-bound P450 (the Saccharomyces cerevisiae sterol 14α-demethylase CYP51A1) with its transmembrane helix intact (Monk et al. 2014). P450s are directed to the mitochondrion by a specific targeting pre-sequence, which is removed by the matrix processing protease, followed by integration of the mature form of the peptide into the mitochondrial inner membrane and exposure of the catalytic core of the P450 to the matrix (Omura 2006). The microsomal and mitochondrial P450s also use distinct redox partner proteins, as explained in the Cytochrome P450 Redox Partner Systems section below.
Structure and Mechanism of Cytochromes P450
The vast majority of P450s perform monooxygenase reactions, catalyzing the reductive scission of molecular oxygen (O2) and the insertion of a single oxygen atom into a substrate bound in the P450 active site, with the second oxygen atom reduced to water according to the scheme:
The structural features of P450 enzymes are intensively studied in order to understand, e.g., how substrates are bound and oxidized, how inhibitors can be designed, and how P450s can be engineered for novel activities. There are currently over 100 unique P450 crystal structures deposited in the Protein Data Bank (PDB, www.rcsb.org), and recent years have seen large increases in the numbers of structures solved for mammalian and other eukaryotic P450 enzymes. The first structurally characterized P450 was the camphor hydroxylase P450cam (CYP101A1) from Pseudomonas putida. This is possibly the most extensively characterized P450 and has provided many important insights into P450 structure/folding and catalytic mechanism (Poulos et al. 1987; Raag and Poulos 1991; Raag et al. 1991). The second P450 structure solved was that of the P450 (heme) domain of the natural P450-cytochrome P450 reductase fusion fatty acid hydroxylase P450 BM3 (CYP102A1, BM3) from Bacillus megaterium (Ravichandran et al. 1993). The P450 BM3 heme domain is structurally related to mammalian CYP4 family fatty acid hydroxylases and also catalyzes fatty acid hydroxylation (Miura and Fulco 1974). These prokaryotic enzymes continue to be important model systems in the P450 superfamily, with BM3 (in particular) proving to be a popular system for protein engineering studies aimed at the introduction of novel catalytic activities (Butler et al. 2013). The P450s share a common structural fold that is well conserved regardless of differences in amino acid sequences, with a triangular prism shape and the heme buried in the center of the molecule (Fig. 3, central image). P450s are predominantly α-helical proteins with a smaller amount of β-sheets. The active site is a substrate-binding pocket of variable size and chemical character (suited to the relevant substrate(s)) above the heme prosthetic group on the opposite face from the thiolate ligand. Conserved secondary structural elements such as the substrate-binding and heme-binding regions, the BC- and FG-helix regions, and the I-helix have subtle variations in their amino acid composition, positions, flexibility, and dynamics that contribute to the diversity of P450 substrate types recognized and the enzymatic reactions catalyzed, despite the overall similarities in P450 structural fold (Poulos and Johnson 2015). Unlike their soluble prokaryotic counterparts, eukaryotic P450s are integral membrane proteins with a single N-terminal transmembrane helical region that tethers them to endoplasmic reticulum or mitochondrial membranes. This presents problems for expression and purification of intact eukaryotic P450s in heterologous hosts and particularly with respect to isolating P450 samples that can be crystallized for structural analysis. However, these issues have been overcome by the deletion of the N-terminal transmembrane regions in a number of eukaryotic P450s, usually together with introduction of additional amino acid mutations that further improve solubility and/or expression of the truncated P450s. The first eukaryotic P450 crystal structure solved was for the Oryctolagus cuniculus (rabbit) progesterone 21-hydroxylase CYP2C5 (Williams et al. 2000), and a number of other eukaryotic P450s have been solved using similar strategies, e.g., rabbit CYP2B4 (Scott et al. 2003). A major breakthrough in eukaryotic P450 crystallography came recently with the determination of the first full-length (membrane-bound) P450 structure of the sterol 14α-demethylase (CYP51F1, also known as ScErg11p) from Saccharomyces cerevisiae that catalyzes the first step in ergosterol biosynthesis. This structure was obtained from CYP51F1 endogenously overexpressed in S. cerevisiae with an engineered His-tag to enable efficient purification. The CYP51F1 structure shows a N-terminal amphipathic helix at the luminal side of the membrane, connected to a transmembrane helix that exposes the P450 catalytic unit on the cytoplasmic side of the lipid bilayer. The P450 substrate-binding region is orientated to face the membrane, from which it likely accesses its natural hydrophobic substrate (lanosterol) (Monk et al. 2014).
Cytochrome P450 Redox Partner Systems
The majority of P450 enzymes require redox partner proteins for functionality. The redox partners transfer electrons derived from NAD(P)H to the substrate-bound P450 at two different steps in the catalytic cycle (Fig. 2). In a productive reaction, the first electron is transferred from the redox partner to the ferric, substrate-bound form reducing it to the ferrous state. In various P450s, this step may be facilitated by an increase in the heme iron FeIII/FeII redox potential that occurs due to a substrate-dependent electronic reorganization in the heme iron d-orbitals, converting the ferric low-spin state to a high-spin state (Daff et al. 1997). The ferrous heme iron can then bind dioxygen and form a ferric-superoxo state, which is then further reduced by the redox partner to form the ferric-peroxo form. Subsequent protonation and dehydration steps lead to the production of compound I, the major species responsible for catalyzing P450 substrate oxidation reactions (Rittle and Green 2010). In eukaryotic P450 systems, the redox partner to the microsomal P450s is NADPH-cytochrome P450 oxidoreductase (abbreviated as CPR or POR), which is a diflavin enzyme (containing FAD and FMN cofactors) that is also bound to the ER membrane by an N-terminal transmembrane anchor region (Waskell and Kim 2015; Fig. 3). The FAD and FMN cofactors reside on two distinct domains of the CPR, with the FMN located in a smaller flavodoxin-like N-terminal domain and FAD bound to the larger C-terminal ferredoxin reductase (FDR)-like domain. NADPH binds to the FDR domain, and two electrons are donated to the CPR FAD as a hydride ion (H−) to reduce this cofactor to its hydroquinone (HQ) state. However, in the cell, it is considered that the CPR FMN cofactor is predominantly in its one-electron reduced semiquinone (SQ) state as a consequence of its high redox potential. The main mechanism for electron transfer from CPR to P450 likely involves a 1-3-2-1 cycle in which the digits reflect the number of electrons on the flavins and in which the FAD HQ passes its two electrons one at a time to the FMN SQ, forming FMN HQ species that donate single electrons to the ferric-superoxo and then the ferric-peroxo species in the catalytic cycle. The FMN HQ has a much lower potential than the FMN SQ, making these reactions feasible, and the CPR inter-domain “hinge” region enables the FMN domain to rotate away from its partner FAD/NADPH-binding domain in order for electron transfers to the P450 (Munro et al. 2013). A similar type of reaction occurs in some soluble, bacterial P450 enzymes, most notably in flavocytochrome P450 BM3 (CYP102A1) in which a soluble CPR (devoid of a membrane anchor region) is covalently attached to a soluble fatty acid hydroxylase P450. This is a biotechnologically important P450 enzyme that has the highest catalytic rate reported for a monooxygenase P450, primarily due to the very fast electron transfer mediated by its fused CPR partner (Noble et al. 1999). However, the BM3 CPR undergoes a 0-2-1-0 cycle in which the CPR is fully oxidized in the resting state and where electrons are delivered to the P450 by an FMN SQ (Hanley et al. 2004). In animals, the mitochondrial P450 redox partner system has similarities to the apparatus used widely in bacteria and archaea, likely consistent with the proposed endosymbiotic origin of mitochondria (Sagan 1967). The partners are the NADPH-dependent, FAD-binding adrenodoxin reductase (ADR) and the 2Fe-2S iron-sulfur cluster-binding protein adrenodoxin (AD). NADPH reduces the ADR FAD to its HQ state, and two single electron transfers from the ADR reduce two oxidized AD clusters from the [2Fe-2S]2+ to the [2Fe-2S]+ state. AD molecules then reduce substrate-bound mitochondrial P450s (primarily involved in steroidogenesis) at the same catalytic cycle stages as described for CPR above (Grinberg et al. 2000).
The CPR (class II) and ADR/AD (class I) redox partner systems represent the major pathways of P450 electron transfer in higher organisms. However, studies in recent years have unveiled a greater diversity of P450 redox partner systems in microbes. These include bacterial/archaeal systems that use FDRs along with different types of ferredoxins (containing 3Fe-4S and 4Fe-4S clusters). For example, an unusual P450 redox partner system was characterized in the thermophilic archaeon Sulfolobus acidocaldarius (formerly S. solfataricus), involving the P450 (CYP119A1), a 2-oxo-acid ferredoxin reductase, and a 7Fe (3Fe-4S and 4Fe-4S)-containing ferredoxin. Hydroxylation of lauric acid at 70 °C was demonstrated using pyruvic acid as an electron source (Puchkaev and Ortiz de Montellano 2005). Another example is the cineole degrading P450cin (CYP176A1) from Citrobacter braakii, in which an FMN-binding flavodoxin (cindoxin) replaces the ferredoxin in a novel class I system and where the P450 catalzyes enantioselective hydroxylation of the monoterpenoid 1,8-cineole (eucalyptol) to form (1R)-6β-hydroxycineole in the pathway to its degradation and use as a carbon source by C. braakii (Stok et al. 2015; Fig. 3).
Biomedical and Biotechnological Aspects of P450s
The P450s catalyze numerous important chemical reactions in humans and other organisms. They are crucial to xenobiotic detoxification and steroid metabolism in mammals and are also key to the production of valuable compounds such as flavors and fragrances (e.g., the sequiterpene (+)-nootkatone), the anti-cancer monoterpene-indole alkaloid drug vinblastine in plants (Cankar et al. 2011; Butler 2008), and antibiotics including the anthelmintic drug avermectin in microbes (Ikeda et al. 1999). As knowledge develops on structural and catalytic properties of P450s, interest has also increased in the engineering of P450s and their applications for producing valuable molecules.
Several mammalian P450 enzymes have pivotal roles in steroid metabolism, with steroid synthesis beginning in the mitochondrion with a three-step oxidation reaction catalyzed by the cholesterol side chain cleaving enzyme CYP11A1 (P450scc) that transforms cholesterol into pregnenolone as the committed step (Fig. 4). Human CYP11A1 deficiencies are very rare but effectively abolish steroid production in gonads and the adrenal cortex (Tajima et al. 2001). Mitochondrial CYP11B1 catalyzes 11β-hydroxylation of deoxycorticosterone to form corticosterone, as does CYP11B2 (aldosterone synthase). Mutations in CYP11B1 result in a form of congenital adrenal hyperplasia called 11β-hydroxylase deficiency, in which the mineralocorticoid deoxycorticosterone accumulates. This results in the masculinization of females due to rerouting of cortisol precursors to androgens. Males and females develop hypertension and low serum potassium later in life and are also prone to adrenal crisis in which low blood pressure results from cortisol deficiency (Auchus and Miller 2015). CYP17A1 (a steroid 17-hydroxylase/17,20-lyase) is a microsomal P450 that catalyzes both the 17-hydroxylation of pregnenolone and progesterone and the 17,20-lyase reaction with the hydroxylated steroids to form dehydroepiandrosterone (DHEA) and androstenedione, respectively. Mutations cause effects that range in severity from partial loss of 17-hydroxylase or 17,20-lyase activity through to complete, combined activity loss. The loss of 17,20-lyase activity prevents synthesis of androgens and estrogens, with catastrophic effects on male and female sexual development (Auchus and Miller 2015). Hepatic P450s are also crucial to oxidative transformations of drugs and other xenobiotics, usually leading to their inactivation and excretion. However, a number of these P450s are also implicated in the activation of chemical carcinogens, including polycyclic hydrocarbons (CYP1A1 and 1B1) and nitrosamines (CYP2A6 and 2E1) (Guengerich 2015). For example, CYP1A1 catalyzes successive hydroxylation and epoxidation reactions on benzo[a]pyrene that transform this cigarette smoke component to carcinogenic and genotoxic (+) and (−) benzo[a]pyrene-7,8-diol-9,10-epoxide products (Shimada and Fujii-Kuriyama 2004). Defects in other human CYP genes are associated with diseases such as rickets (CYP2R1, CYP27B1) and hypercholesterolemia (CYP7A1) (Pikuleva and Waterman 2013).
Important biotechnological applications of P450s include the engineering of these enzymes, using either directed evolution (DE) approaches (i.e., random or semi-random mutagenesis of the relevant P450 combined with screening of mutants for desired properties) or structure-guided mutagenesis to produce novel variants with desirable catalytic properties. The high activity mid- to long-chain fatty acid hydroxylase P450-CPR fusion enzyme P450 BM3 has proven an excellent template for such programs. Notable successes include BM3’s conversion to a hydroxylase of short chain alkanes and to an enantioselective epoxidase of terminal alkenes using DE approaches (Peters et al. 2003; Kubo et al. 2006). Other DE and rational mutagenesis studies have produced BM3 mutants that generate human drug metabolites that replicate those produced by the relevant human P450s. Examples include metabolites of the gastric proton pump inhibitor (PPI) omeprazole and of other PPI drugs (Butler et al. 2013, 2014) and of diverse drugs such as chlorzoxazone, lidocaine, and diclofenac (Ren et al. 2015). The effective production of bona fide human drug metabolites has become increasingly important due to FDA requirements for toxicity testing of major human drug metabolites as well as their parent drugs (Guengerich 2015). In other work, Frances Arnold’s group demonstrated that BM3 could be used to catalyze the asymmetric cyclopropanation of styrenes, with the efficiency of the reaction enhanced considerably in the T286A mutant in which a residue crucial to efficient monooxygenation chemistry is substituted (Coelho et al. 2013a). Cyclopropanation of olefins is widely used in fine chemical synthesis, and further studies showed more efficient cyclopropanation of stytrenes both in vivo (E. coli cells) and in vitro, using the diazoester ethyl diazoacetate for carbene transfer in a BM3 variant in which the cysteine thiolate ligand was mutated to a serine, resulting in a large increase in potential of the heme iron and abolition of monooxygenase activity (Coelho et al. 2013b). A quadruple mutant of BM3 was also used for the conversion of amorpha-4,11-diene to its epoxide in a semisynthetic pathway for the production of the antimalarial artemisinin (Dietrich et al. 2009). Eukaryotic P450s also provided a test case for Stephen Sligar and colleagues in the development of nanodisc technology. Nanodiscs are discoidal membrane bilayers that are stabilized and made soluble in aqueous solution through their being encircled by two amphipathic helical protein belts known as membrane scaffold proteins. Purified, detergent solubilized P450s and other membrane proteins are typically assembled into nanodiscs by mixing with scaffold protein and phospholipids at appropriate stoichiometry, followed by detergent removal using hydrophobic beads (Denisov and Sligar 2016). Examples of the use of this novel technology on P450 redox systems include its application for the analysis of the influence of the nanodisc membrane bilayer and its lipid composition on the redox potentials of the CPR flavin cofactors and to explore the complex catalytic mechanism of the CYP17A1 P450 that converts pregnenolone to dehydroepiandrosterone (Das and Sligar 2009; Gregory et al. 2013). Other recent studies have demonstrated how light can be used to drive P450 function directly though covalent attachment of a RuII-diimine complex to the BM3 heme domain. The ruthenium “photosensitizer” is continuously reduced photocatalytically to the RuI state, which passes electrons to the heme iron and enables fatty acid hydroxylation (Tran et al. 2013). The cyanobacterium Synechocystis sp. PCC6803 was also engineered by introduction of a vector encoding two plant P450s (CYP79A1 and CYP71E1) and a glycosyltransferase that transform L-tyrosine into the cyanogenic glucoside and insect antifeedant dhurrin. The P450s were successfully incorporated into the cyanobacterial thylakoid membranes, close to photosynthetic complexes, and catalysis was driven by light though electron transfer via photosystem I and ferredoxin to the P450s, producing both dhurrin and the pathway precursor p-hydroxyphenylacetaldoxime (Wlodarczyk et al. 2016).
The P450s are remarkable catalysts that are able to perform a myriad of different chemical reactions. They span all the major domains of life and were the first protein group classified into an enzyme “superfamily”. P450s have pivotal roles in animal health, particularly with respect to the metabolism of steroids, other lipids, and xenobiotics. P450 deficiencies are implicated in several human diseases, and the activities of mammalian xenobiotic metabolizing P450 enzymes with compounds such as arylamines and polycyclic aromatic hydrocarbons can result in the activation of these chemical carcinogens. In plants and microbes, P450s have diverse roles in the synthesis of molecules such as terpenoids, alkaloids, macrolide antibiotics, and mycotoxins. Large numbers of P450s are found in Streptomyces and other bacteria, where they are involved in the production of industrially important molecules such as the antibiotics erythromycin and vancomycin and the anthelmintic avermectin. Numerous P450s are also encoded in the genome of the pathogen Mycobacterium tuberculosis, where they are implicated in bacterial secondary metabolism, in regulation of respiration through modification of respiratory menaquinone, and in bacterial infection and survival in the macrophage through their role in catabolism of host cholesterol. The astonishing array of oxidative and other activities associated with P450s has been further expanded through characterization of the properties of engineered variants of biotechnologically important P450s, and these enzymes are increasingly utilized in the industrial scale production of high-value compounds, such as the antimalarial artemisinin and the cholesterol-lowering drug pravastatin (Dietrich et al. 2009; McLean et al. 2014). The diverse roles of the P450s in areas such as human and animal health, biotechnology, and synthetic biology reveal “Nature’s most versatile catalyst” to be of economic importance, with several potential applications in areas such as chemical synthesis, bioremediation, and human medicine (Coon 2005; Rylott et al. 2011).
- Auchus RJ, Miller WL. P450 enzymes in steroid processing. In: Ortiz de Montellano PR, editor. Cytochromes P450: structure, mechanism and biochemistry. 4th ed. New York: Springer; 2015. p. 851–79.Google Scholar
- Belcher J, McLean KJ, Matthews S, Woodward LS, Fisher K, Rigby SE, Nelson DR, Potts D, Baynham MT, Parker DA, Leys D, Munro AW. Structure and biochemical properties of the alkene producing cytochrome P450 OleTJE (CYP152L1) from the Jeotgalicoccus sp. 8456 bacterium. J Biol Chem. 2014;289(10):6535–50.CrossRefPubMedPubMedCentralGoogle Scholar
- Cole ST, Brosch R, Parkhill J, Garnier T, Churcher C, Harris D, Gordon SV, Eiglmeier K, Gas S, Barry 3rd CE, Tekaia F, Badcock K, Basham D, Brown D, Chillingworth T, Connor R, Davies R, Devlin K, Feltwell T, Gentles S, Hamlin N, Holroyd S, Hornsby T, Jagels K, Krogh A, McLean J, Moule S, Murphy L, Oliver K, Osborne J, Quail MA, Rajandream MA, Rogers J, Rutter S, Seeger K, Skelton J, Squares R, Squares S, Sulston JE, Taylor K, Whitehead S, Barrell BG. Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence. Nature. 1998;393(6685):537–44.CrossRefPubMedGoogle Scholar
- Cole ST, Eiglmeier K, Parkhill J, James KD, Thomson NR, Wheeler PR, Honoré N, Garnier T, Churcher C, Mungall K, Basham D, Brown D, Chillingworth T, Connor R, Davies RM, Devlin K, Duthoy S, Feltwell T, Fraser A, Hamlin N, Holroyd S, Hornsby T, Jagels K, Lacroicx C, MacLean J, Moule S, Murphy L, Oliver K, Quail MA, Rajandream MA, Rutherford KM, Rutter S, Seeger K, Simon S, Simmonds M, Skelton J, Squares R, Squares S, Taylor K, Whitehead S, Woodward JR, Barrell BG. Massive gene decay in the leprosy Bacillus. Nature. 2001;409(6823):1007–11.CrossRefPubMedGoogle Scholar
- Driscoll MD, McLean KJ, Levy C, Mast N, Pikuleva IA, Lafite P, Rigby SE, Leys D, Munro AW. Structural and biochemical characterization of Mycobacterium tuberculosis CYP142: evidence for multiple cholesterol 27-hydroxylase activities in a human pathogen. J Biol Chem. 2010;285(49):38270–82.CrossRefPubMedPubMedCentralGoogle Scholar
- Dunford AJ, McLean KJ, Sabri M, Seward HE, Heyes DJ, Scrutton NS, Munro AW. Rapid P450 heme iron reduction by laser photoexcitation of Mycobacterium tuberculosis CYP121 and CYP51B1. Analysis of CO complexation reactions and reversibility of the P450/P420 equilibrium. J Biol Chem. 2007;282(34):24816–24.CrossRefPubMedGoogle Scholar
- Edin ML, Cheng J, Gruzdev A, Hoopes SL, Zeldin DC. P450 enzymes in lipid oxidation. In: Ortiz de Montellano PR, editor. Cytochromes P450: structure, mechanism and biochemistry. 4th ed. New York: Springer; 2015. p. 881–905.Google Scholar
- Enright JM, Toomey MB, Sato SY, Temple SE, Allen JR, Fujiwara R, Kramlinger VM, Nagy LD, Johnson KM, Xiao Y, How MJ, Johnson SL, Roberts NW, Kefalov VJ, Guengerich FP, Corbo JC. Cyp27c1 red-shifts the spectral sensitivity of photoreceptors by converting vitamin A1 into A2. Curr Biol. 2015;25(23):3048–57.CrossRefPubMedPubMedCentralGoogle Scholar
- Fujishiro T, Shoji O, Nagano S, Sugimoto H, Shiro Y, Watanabe Y. Crystal structure of H2O2-dependent cytochrome P450SPα with its bound fatty acid substrate: insight into the regioselective hydroxylation of fatty acids at the alpha position. J Biol Chem. 2011;286(34):29941–50.CrossRefPubMedPubMedCentralGoogle Scholar
- Guengerich FP. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochromes P450: structure, mechanism and biochemistry. 4th ed. New York: Springer; 2015. p. 523–785.Google Scholar
- Holt RA, Subramanian GM, Halpern A, Sutton GG, Charlab R, Nusskern DR, Wincker P, Clark AG, Ribeiro JM, Wides R, Salzberg SL, Loftus B, Yandell M, Majoros WH, Rusch DB, Lai Z, Kraft CL, Abril JF, Anthouard V, Arensburger P, Atkinson PW, Baden H, de Berardinis V, Baldwin D, Benes V, Biedler J, Blass C, Bolanos R, Boscus D, Barnstead M, Cai S, Center A, Chaturverdi K, Christophides GK, Chrystal MA, Clamp M, Cravchik A, Curwen V, Dana A, Delcher A, Dew I, Evans CA, Flanigan M, Grundschober-Freimoser A, Friedli L, Gu Z, Guan P, Guigo R, Hillenmeyer ME, Hladun SL, Hogan JR, Hong YS, Hoover J, Jaillon O, Ke Z, Kodira C, Kokoza E, Koutsos A, Letunic I, Levitsky A, Liang Y, Lin JJ, Lobo NF, Lopez JR, Malek JA, TC MI, Meister S, Miller J, Mobarry C, Mongin E, Murphy SD, DA O’B, Pfannkoch C, Qi R, Regier MA, Remington K, Shao H, Sharakhova MV, Sitter CD, Shetty J, Smith TJ, Strong R, Sun J, Thomasova D, Ton LQ, Topalis P, Tu Z, Unger MF, Walenz B, Wang A, Wang J, Wang M, Wang X, Woodford KJ, Wortman JR, Wu M, Yao A, Zdobnov EM, Zhang H, Zhao Q, Zhao S, Zhu SC, Zhimulev I, Coluzzi M, della Torre A, Roth CW, Louis C, Kalush F, Mural RJ, Myers EW, Adams MD, Smith HO, Broder S, Gardner MJ, Fraser CM, Birney E, Bork P, Brey PT, Venter JC, Weissenbach J, Kafatos FC, Collins FH, Hoffman SL. The genome sequence of the malaria mosquito Anopheles gambiae. Science. 2002;298(5591):129–49.CrossRefPubMedGoogle Scholar
- McLean KJ, Leys D, Munro AW. Microbial cytochromes P450. In: Ortiz de Montellano PR, editor. Cytochromes P450: structure, mechanism and biochemistry. 4th ed. New York: Springer; 2014. p. 261–407.Google Scholar
- McLean KJ, Hans M, Meijrink B, van Scheppingen WB, Vollebregt A, Tee KL, van der Laan JM, Leys D, Munro AW, van den Berg MA. Single-step fermentative production of the cholesterol-lowering drug pravastatin via reprogramming of Penicillium chrysogenum. Proc Natl Acad Sci U S A. 2015;112(9):2847–52.CrossRefPubMedPubMedCentralGoogle Scholar
- Monk BC, Tomasiak TM, Keniya MV, Huschmann FU, Tyndall JD, O’Connel J, Cannon RD, McDonald JG, Rodriguez A, Finer-Moore JS, Stroud RM. Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer. Proc Natl Acad Sci U S A. 2014;111:3865–70.CrossRefPubMedPubMedCentralGoogle Scholar
- Nebert DW, Nelson DR, Coon MJ, Estabrook RW, Feyereisen R, Fujii-Kuriyama Y, Gonzalez FJ, Guengerich FP, Gunsalus IC, Johnson EF, Loper JC, Sato R, Waterman MR, Waxman DJ. The P450 superfamily: update on new sequences, gene mapping, and recommended nomenclature. DNA Cell Biol. 1991;10(1):1–14.CrossRefPubMedGoogle Scholar
- Nelson DR. http://drnelson.uthsc.edu/trypb.html. 2004. Accessed 17 Oct 2016.
- Nelson DR. http://drnelson.uthsc.edu/Aspergillus.htm. 2007. Accessed 17 Oct 2016.
- Nelson DR. http://drnelson.uthsc.edu/Nomenclature.html. 2009. Accessed 18 Oct 2016.
- Nelson DR. http://drnelson.uthsc.edu/tomato.html. 2012. Accessed 17 Oct 2016.
- Nelson DR. http://drnelson.uthsc.edu/bos.2015.htm. 2015. Accessed 17 Oct 2016.
- Nelson DR. http://drnelson.uthsc.edu/P450statistics. April 2016 (png). Accessed 17 Oct 2016.
- Omura T, Sato R. The carbon monoxide binding pigment of liver microsomes I. Evidence for its hemoprotein nature. J Biol Chem. 1964;7:2370–8.Google Scholar
- Poulos TL, Johnson EF. Structures of cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochromes P450: structure, mechanism and biochemistry. 4th ed. New York: Springer; 2015. p. 3–32.Google Scholar
- Schuler MA. P450s in plants, insects and their fungal pathogens. In: Ortiz de Montellano PR, editor. Cytochromes P450: structure, mechanism and biochemistry. 4th ed. New York: Springer; 2015. p. 409–49.Google Scholar
- UCSC Microbial Genome Browser. http://microbes.ucsc.edu/cgi-bin/hgGateway?clade=bacteria-actinobacteria. Accessed 17 Oct 2016.
- Warman AJ, Robinson JW, Luciakova D, Lawrence AD, Marshall KR, Warren MJ, Cheesman MR, Rigby SEJ, Munro AW, McLean KJ. Characterization of Cupriavidus metallidurans CYP116B1 – a thiocarbamate herbicide oxygenating P450-phthalate dioxygenase reductase fusion protein. FEBS Lett. 2012;279(9):1675–93.CrossRefGoogle Scholar
- Waskell L, Kim J-JP. Electron transfer partners of cytochrome P450. In: Ortiz de Montellano PR, editor. Cytochromes P450: structure, mechanism and biochemistry. 4th ed. New York: Springer; 2015. p. 33–68.Google Scholar
- Wlodarczyk A, Gnanasekaran T, Nielsen AZ, Zulu NN, Mellor SB, Luckner M, Thøfner JFB, Olsen CE, Mottawie MS, Burow M, Pribil M, Feussner I, Møller BL, Jensen PE. Metabolic engineering of light-driven cytochrome P450 dependent pathways into Synechocystis sp. PCC6803. Metab Eng. 2016;33:1–11.CrossRefPubMedGoogle Scholar